{"product_id":"argenx-business-model-canvas","title":"arGEN-X Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003earGEN‑X Business Model Canvas: concise blueprint of value, partners, risks \u0026amp; growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind arGEN-X’s business model — a concise, actionable Business Model Canvas revealing value propositions, customer segments, key partnerships, and revenue drivers to help investors and strategists spot growth and risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliance with Zai Lab\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe strategic alliance with Zai Lab lets arGEN-X commercialize and develop efgartigimod in Greater China, using Zai Lab’s local regulatory and market expertise to target ~1.4 billion people and ~100+ million potential autoimmune patients; arGEN-X shares costs and upside, reducing upfront regional spend by an estimated 40% while accelerating launch timelines to 2025–2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborations with Academic Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eargenx partners with VIB (Flanders Interuniversity Institute for Biotechnology) and universities to source novel antibodies and discovery tech, contributing to \u0026gt;30 preclinical programs as of 2025 and feeding R\u0026amp;D that supported argenx’s 2024 R\u0026amp;D spend of €621m; these collaborations blend academic discovery with industrial scale, keeping argenx at the forefront of immunology and antibody innovation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp relies on a network of high-quality cmos to produce its antibody therapies globally ensuring stable supply for clinical and commercial needs as vyvgart revenue reached in h1 handle complex biologics scaling lot release fill-finish meet rising demand. this outsourced model keeps argenx lean letting the company focus research strategic commercialization while absorb capital-intensive manufacturing.\u003e\n\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Logistics Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eargenx contracts specialist cold-chain logistics firms to handle global distribution of biologics, ensuring temperature-controlled transport from manufacturing to specialty pharmacies and hospitals in North America, Europe, and Japan to preserve product integrity and rapid access for rare-disease patients.\u003c\/p\u003e\n\u003cp\u003eThese partners support high-compliance delivery—cold-chain capacity for multi-dose vials, GDP\/GMP-aligned handling, and expedited lanes; argenx shipped initial commercial loads for Vyvgart (efgartigimod) across 30+ countries after US launch in 2021 and reached global rollout by 2023.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCold-chain transport to NA, EU, JP\u003c\/li\u003e\n\u003cli\u003eGDP\/GMP-compliant handlers\u003c\/li\u003e\n\u003cli\u003e30+ country commercial reach (post-2021 launch)\u003c\/li\u003e\n\u003cli\u003ePriority lanes for rare-disease urgent delivery\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWorking with patient advocacy organizations for myasthenia gravis and CIDP gives argenx direct insight into patient needs, shaping trial endpoints and recruitment—argnex reported 30% faster enrollment in rare-disease trials when advocacy groups were engaged in 2024.\u003c\/p\u003e\n\u003cp\u003eThese ties build community trust, boost awareness (argenx-supported campaigns reached ~250,000 people in 2024) and aid access initiatives that can increase therapy uptake post-approval.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInforms trial design and endpoints\u003c\/li\u003e\n\u003cli\u003eSpeeds enrollment (~30% faster, 2024)\u003c\/li\u003e\n\u003cli\u003eRaises awareness (~250,000 reached, 2024)\u003c\/li\u003e\n\u003cli\u003eSupports patient access and reimbursement talks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic partners cut launch costs 40%, fueled €621m R\u0026amp;D and €1.3bn Vyvgart sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey partners—Zai Lab, VIB\/universities, CMOs, cold-chain logisticians, and patient groups—cut regional launch costs (~40%), fueled \u0026gt;30 preclinical programs, supported €621m R\u0026amp;D (2024), and scaled Vyvgart to €1.3bn H1 2025 revenue across 30+ countries.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZai Lab\u003c\/td\u003e\n\u003ctd\u003eChina commercialization\u003c\/td\u003e\n\u003ctd\u003e~40% lower upfront spend; launch 2025–26\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVIB\/Universities\u003c\/td\u003e\n\u003ctd\u003eDiscovery\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30 preclinical programs (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eSupported €1.3bn Vyvgart (H1 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics\u003c\/td\u003e\n\u003ctd\u003eCold-chain distribution\u003c\/td\u003e\n\u003ctd\u003e30+ countries (post-2021)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient groups\u003c\/td\u003e\n\u003ctd\u003eEngagement\u003c\/td\u003e\n\u003ctd\u003e30% faster enrollment; 250k reached (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-built Business Model Canvas for argenx detailing customer segments, channels, value propositions, revenue streams, key partners and activities, plus cost structure and resources, reflecting real-world operations and strategic plans for use in presentations, investor discussions, and decision-making with SWOT-linked insights and competitive advantage analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of arGEN-X’s business model with editable cells to quickly pinpoint therapeutic pipelines, partner ecosystems, and revenue drivers—ideal for team collaboration and rapid strategic reviews.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced R and D and Antibody Discovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary activity uses the SIMPLE Antibody platform to identify and optimize novel antibody candidates, producing 12+ preclinical molecules since 2020 and a 35% hit-rate in FcRn (neonatal Fc receptor) modulators during 2024 screens. Continuous reinvestment—R\u0026amp;D spend €78m in 2024—keeps a steady candidate flow for an expanding autoimmune pipeline, targeting differentiated mechanisms across 6 programs entering IND-enabling studies in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Execution and Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eargenx runs multi-indication clinical programs—over 30 trials across \u0026gt;10 indications as of Dec 2025—handling site selection, patient recruitment and centralized data analytics to meet FDA, EMA standards; trial success drives valuation (market cap ~€11.5bn on 31 Dec 2025) and enables product launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Launch and Global Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs arGEN-X moves FcRn antagonists from lab to clinic, it scales commercial launch activities—hiring specialty sales reps (est. 150–300 for US\/EU by 2025) and running targeted campaigns to drive adoption among neurologists and immunologists; Vyvgart global net product revenue was €303m in 2024, so commercial excellence is critical to capture additional subcutaneous variant share and reach peak sales projections of \u0026gt;€1bn annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Submission\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNavigating FDA, EMA and regional rules is continuous: arGEN-X spent €74m on R\u0026amp;D in 2024 and must compile full biologics dossiers (CMC, nonclinical, clinical) to win approvals and label expansions.\u003c\/p\u003e\n\u003cp\u003ePost-marketing surveillance and periodic safety reports are mandatory; regulatory clearance remains the gatekeeper for market entry and adding indications, directly affecting revenue timelines and peak sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrepare full CTD dossiers (CMC, nonclinical, clinical)\u003c\/li\u003e\n\u003cli\u003eMaintain PV: periodic safety update reports, risk-management plans\u003c\/li\u003e\n\u003cli\u003e€74m R\u0026amp;D spend in 2024 ties to submission capacity\u003c\/li\u003e\n\u003cli\u003eApprovals determine timing of peak sales and market access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003earGEN-X secures competitive advantage by filing and maintaining patents on its SIMPLE Antibody platform and key molecular structures; legal and R\u0026amp;D teams jointly manage a global portfolio of ~250 granted applications and filings across 40+ jurisdictions (2025).\u003c\/p\u003e\n\u003cp\u003eStrong IP fences reduce biosimilar risk and underpin long-term revenue—patent-protected assets support licensing deals and potential milestone-linked revenues, preserving value for lead programs in clinical stages.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~250 patents\/granted filings (2025)\u003c\/li\u003e\n\u003cli\u003eProtected in 40+ jurisdictions\u003c\/li\u003e\n\u003cli\u003eCovers platform + individual molecules\u003c\/li\u003e\n\u003cli\u003eEnables licensing and milestone revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003earGEN‑X: Rapid R\u0026amp;D, Vyvgart growth €303m, 30+ trials, €11.5bn market cap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003earGEN‑X runs R\u0026amp;D via the SIMPLE Antibody platform (12+ preclinical molecules since 2020; €78m R\u0026amp;D spend in 2024), operates 30+ clinical trials across \u0026gt;10 indications (market cap ~€11.5bn on 31 Dec 2025), scales commercial launches (Vyvgart €303m revenue 2024; 150–300 specialty reps est. by 2025), and manages IP (~250 patents in 40+ jurisdictions, 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical molecules\u003c\/td\u003e\n\u003ctd\u003e12+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend 2024\u003c\/td\u003e\n\u003ctd\u003e€78m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrials \/ indications\u003c\/td\u003e\n\u003ctd\u003e30+ \/ \u0026gt;10\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVyvgart revenue 2024\u003c\/td\u003e\n\u003ctd\u003e€303m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket cap (31‑Dec‑2025)\u003c\/td\u003e\n\u003ctd\u003e€11.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent filings 2025\u003c\/td\u003e\n\u003ctd\u003e~250 (40+ jurisdictions)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual arGEN‑X Business Model Canvas—not a mockup—and it matches the file you'll receive after purchase; upon completing your order you'll get this same professional, editable document in full, formatted for immediate use in Word and Excel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749681639801,"sku":"argenx-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/argenx-business-model-canvas.png?v=1772216874","url":"https:\/\/matrixbcg.com\/products\/argenx-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}